The estimated Net Worth of Michael A Darwin is at least 23.6 千$ dollars as of 31 July 2008. Michael Darwin owns over 1,709 units of Biocryst Pharmaceuticals stock worth over 23,561$ and over the last 21 years Michael sold BCRX stock worth over 0$.
Michael has made over 5 trades of the Biocryst Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Michael bought 1,709 units of BCRX stock worth 4,819$ on 31 July 2008.
The largest trade Michael's ever made was exercising 22,650 units of Biocryst Pharmaceuticals stock on 15 March 2006 worth over 65,912$. On average, Michael trades about 3,202 units every 164 days since 2004. As of 31 July 2008 Michael still owns at least 3,048 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Michael Darwin stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 2190 PARKWAY LAKE DR, , BIRMINGHAM, AL, 35244.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over 76,362,383$ worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth 20,848,654$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Brothers Life Sciences Capi...、Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of 542,329$. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth 54,352$.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: